[{"id":"659160cb-410e-4379-bdd3-f303bb40e1fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05094336","created_at":"2021-10-26T20:53:08.844Z","updated_at":"2025-02-25T13:54:05.475Z","phase":"Phase 1/2","brief_title":"A Study of AMG 193 in Subjects With Advanced MTAP-[] Solid Tumors","source_id_and_acronym":"NCT05094336","lead_sponsor":"Amgen","biomarkers":" CDKN2A • MTAP","pipe":"","alterations":" ","tags":["CDKN2A • MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • AMG 193"],"overall_status":"Recruiting","enrollment":" Enrollment 649","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 08/02/2026","primary_completion_date":" 08/02/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-20"},{"id":"d4485f54-359c-4ee3-8554-f4f3c66c58bb","acronym":"TNG462-C101","url":"https://clinicaltrials.gov/study/NCT05732831","created_at":"2023-02-17T15:00:50.938Z","updated_at":"2025-02-25T14:41:52.620Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","source_id_and_acronym":"NCT05732831 - TNG462-C101","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vopimetostat (TNG462)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 05/26/2023","start_date":" 05/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-14"},{"id":"4f30abc8-8e7a-46eb-9dd2-cdd5a80eaef4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06810544","created_at":"2025-02-25T16:50:18.957Z","updated_at":"2025-02-25T16:50:18.957Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","source_id_and_acronym":"NCT06810544","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 191","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-05"},{"id":"6e960e10-a292-4eb9-ac61-0062dbf094ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05975073","created_at":"2023-08-03T15:09:55.318Z","updated_at":"2024-07-02T16:34:37.673Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors","source_id_and_acronym":"NCT05975073","lead_sponsor":"Amgen","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDE397 • AMG 193"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 12/03/2026","study_completion_date":" 12/03/2026","last_update_posted":"2024-06-06"},{"id":"f8a566d4-1220-4795-a41e-999d20763d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT05245500","created_at":"2022-02-18T14:52:54.785Z","updated_at":"2024-07-02T16:34:59.606Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion","source_id_and_acronym":"NCT05245500","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navlimetostat (BMS‐986504)"],"overall_status":"Recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-06-03"},{"id":"a89145ed-d1fb-47bb-8570-547616d247d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275478","created_at":"2022-03-11T15:53:41.554Z","updated_at":"2024-07-02T16:34:59.862Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors","source_id_and_acronym":"NCT05275478","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNG908"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-31"},{"id":"0ff63797-5bfd-4773-893e-1563164054ca","acronym":"OTT-19-06","url":"https://clinicaltrials.gov/study/NCT04676516","created_at":"2021-01-19T20:45:48.594Z","updated_at":"2025-02-25T13:19:48.698Z","phase":"Phase 2","brief_title":"A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer","source_id_and_acronym":"NCT04676516 - OTT-19-06","lead_sponsor":"Ottawa Hospital Research Institute","biomarkers":" HER-2 • ER • TP53 • PGR • CD8 • CD4 • FOXP1","pipe":" | ","alterations":" HER-2 negative • TP53 wild-type • PGR positive","tags":["HER-2 • ER • TP53 • PGR • CD8 • CD4 • FOXP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • TP53 wild-type • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemrametostat (GSK3326595)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 08/15/2022","study_completion_date":" 08/15/2022","last_update_posted":"2022-10-25"}]